Prot #I5B-IE-JGDG: A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without Anti-PDGFRx Monoclonal Antibody (IMC-3G3) in the treatment of Advanced Soft Tissue Sarcoma

  • Agulnik, Mark (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date2/9/11 → 2/14/17

Funding

  • Eli Lilly and Company (Prot #I5B-IE-JGDG)